Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies

Objective To evaluate the 104-week safety of dapagliflozin in older patients with type 2 diabetes mellitus. Methods Pooled analysis assessing general safety (nine phase III studies ≤104 weeks) and cardiovascular safety (21 phase IIb/III studies ≤208 weeks) by age (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs & aging 2016-07, Vol.33 (7), p.511-522
Hauptverfasser:	Fioretto, Paola, Mansfield, Traci A., Ptaszynska, Agata, Yavin, Yshai, Johnsson, Eva, Parikh, Shamik
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - adverse effects Benzhydryl Compounds - therapeutic use Cardiovascular Diseases - epidemiology Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Diabetes Mellitus, Type 2 - drug therapy Female Fractures, Bone - chemically induced Fractures, Bone - epidemiology Geriatrics/Gerontology Glucosides - administration & dosage Glucosides - adverse effects Glucosides - therapeutic use Humans Hypoglycemia - chemically induced Hypoglycemia - epidemiology Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Internal Medicine Kidney - physiopathology Male Medicine Medicine & Public Health Middle Aged Original Original Research Article Pharmacology/Toxicology Pharmacotherapy Risk Factors Safety Urinary Tract Infections - chemically induced Urinary Tract Infections - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective To evaluate the 104-week safety of dapagliflozin in older patients with type 2 diabetes mellitus. Methods Pooled analysis assessing general safety (nine phase III studies ≤104 weeks) and cardiovascular safety (21 phase IIb/III studies ≤208 weeks) by age (
ISSN:	1170-229X 1179-1969
DOI:	10.1007/s40266-016-0382-1